BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Department of Chemical Engineering - ECPv6.17.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://che.northeastern.edu
X-WR-CALDESC:Events for Department of Chemical Engineering
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260930T120000
DTEND;TZID=America/New_York:20260930T130000
DTSTAMP:20260903T144707Z
CREATED:20260903T144707Z
LAST-MODIFIED:20260903T144707Z
UID:6164-1790769600-1790773200@che.northeastern.edu
SUMMARY:Chemical Engineering Fall Seminar Series: Trevor Sherwood
DESCRIPTION:Discovery of BMS-986526\, an EP4 agonist for the treatment of IBD using a direct-to-biology platform \nLocation: 108 Snell Engineering Center \nAbstract: This seminar will cover a brief overview of medicinal chemistry and the discovery of an EP4 agonist for IBD. The EP4 receptor is a GPCR expressed in multiple tissues. In the intestines\, the activation of EP4 is linked to restitution of the intestinal epithelial barrier and anti-inflammatory effects on immune cells\, making it a target of interest for IBD. However\, EP4 expression in other tissues complicates the utility of EP4 agonists. For instance\, EP4 agonism in systemic circulation has been shown to result in changes in heart rate and blood pressure. We set out to identify selective EP4 agonists with minimal systemic exposure outside of the gastrointestinal tract. Our campaign began with a high throughput screen which identified a triazine chemotype that was elaborated into a lead compound which demonstrated high circulating exposure. To identify compounds with lower exposure\, a direct-to-biology campaign leveraging a nanosynthesis platform was undertaken\, enabling us to rapidly explore novel chemical space and identify BMS-986526\, a lead that was subsequently nominated as a development candidate. This presentation will describe our lead chemotype\, the execution of our nanosynthesis and direct-to-biology campaign\, and the in vivo profile of BMS-986526 and other related lead compounds. \n\nTrevor Sherwood is a Scientific Associate Director in the Bristol Myers Squibb Discovery Chemistry group in Princeton\, NJ. He earned his B.S. in chemistry at Rensselaer Polytechnic Institute in 2008 and then earned his Ph.D. in 2013 with Prof. Scott Snyder at Columbia University where he completed multiple total syntheses of alkaloid and polyphenolic natural products. In 2013\, Trevor joined BMS where he has performed research in immunology\, oncology\, and neuroscience and has led multiple drug discovery programs. He is passionate about LGBTQ representation in chemistry and co-organized a session at the 2024 Spring ACS National Meeting featuring presentations from LGBTQ medicinal chemists.
URL:https://che.northeastern.edu/event/chemical-engineering-fall-seminar-series-trevor-sherwood/
LOCATION:108 SN
END:VEVENT
END:VCALENDAR